AR067445A1 - Inhibidores tetrahidropiranocromeno de gamma secretasa - Google Patents
Inhibidores tetrahidropiranocromeno de gamma secretasaInfo
- Publication number
- AR067445A1 AR067445A1 ARP080102867A ARP080102867A AR067445A1 AR 067445 A1 AR067445 A1 AR 067445A1 AR P080102867 A ARP080102867 A AR P080102867A AR P080102867 A ARP080102867 A AR P080102867A AR 067445 A1 AR067445 A1 AR 067445A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- substituted
- group
- groups
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 150000003512 tertiary amines Chemical class 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001336 alkenes Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000005667 attractant Substances 0.000 abstract 1
- 230000031902 chemoattractant activity Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- -1 sulfonyl anhydride Chemical class 0.000 abstract 1
- 150000003461 sulfonyl halides Chemical class 0.000 abstract 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
También se describen métodos de inhibir a gamma-secretasa, métodos de tratar enfermedades neurodegenerativas, y métodos de tratar enfermedad de Alzheimer. También se describen procesos para preparar alquenos en un paso de reaccion usando una mezcla de un aldehído (o cetona) y un alquilo sustituido con dos grupos atrayentes de electrones y la reaccion de la mezcla con: (a) un haluro de sulfonilo (por ej., un cloruro de sulfonilo) y una amina terciaria básica, o, (b) un anhídrido de sulfonilo y una amina básica, o (c) un aril-C(O)-haluro y una amina terciaria básica, o (d) un aril-C(O)-O-C(O)-arilo y una amina terciaria básica, o (e) un heteroaril-C(O)-haluro y una amina terciaria básica, o (f) un heteroaril-C(O)-O-C(O)- heteroarilo y una amina terciaria básica. Reivindicacion 1: Un compuesto de la formula: (1) o una de sus sales, solvatos o ésteres aceptables para uso farmacéutico, en donde: X se selecciona del grupo que consiste en N y CH2; R1 se selecciona del grupo que consiste en: (1) -alquilen-S(O)2-alquilo(C1-6), (2) -alquilen-S(O)2-haloalquilo(C1-5); (3) -alquilen-S(O)2-R6, (4) -alquilen-S(O)2-R8, (5) -alquilen-S(O)2-alquiloC1-6) sustituido, (6) -alquilen-(1,1-dioxido de tetrahidrotiofeno), (7) -alquenil-S(O)2-alquilo(C1-6), y (8) -cicloalquil-S(O)2-alquilo(C1-6); en donde dicho grupo R1 -alquilen-S(O)2-alquilo(C1-6) sustituido está sustituido con uno o más sustituyentes seleccionados de modo independiente del grupo que consiste en: -OH, halo, -CN, -CF3, -O-alquilo(C1-6), y -O-(haloalquilo(C1-6)); R2 se selecciona del grupo que consiste en: H y alquilo; R6 se selecciona del grupo que consiste en: (1) arilo (C6-14) no sustituido, (2) arilo (C6-14) sustituido con uno o más grupos L1A, (3) heteroarilo (C5-14) no sustituido, (4) heteroarilo (C5-14) sustituido con uno o más grupos L1A, (5) heteroarilalquilo(C5-14) no sustituido, y (5) heteroarilalquilo (C5-14) sustituido con uno o más grupos L1A; R8 se selecciona del grupo que consiste en cicloalquilo no sustituido y cicloalquilo sustituido con uno o más grupos L3 (en donde los ejemplos de dichos grupos cicloalquilo (no sustituido o sustituido) incluyen anillos cicloalquilo C3-10); cada L3 se selecciona de modo independiente del grupo que consiste en: (1) -CN, (2) =O, (3) -CH2OH, (4) amino, (5) halo, (6) -CH2NH2, (7) -CH2NHalquilo, (8) -C(O)OH, (9) -alquilen-C(O)NH alquilo (C1-6), (10) -alquilen-C(O)N(alquilo (C1-6))2 en donde cada alquilo se selecciona de modo independiente, (11) -alquilen-C(O)NH haloalquilo (C1-6), y (12) -alquilen-C(O)N(haloalquilo (C1-6))2 en donde cada alquilo se selecciona de modo independiente); Ar se selecciona del grupo que consiste en: (1) arilo no sustituido, (2) arilo sustituido con uno o más grupos L1A, (3) heteroarilo no sustituido, y (4) heteroarilo sustituido con uno o más grupos L1A; cada L1 se selecciona de modo independiente del grupo que consiste en: halogeno, alquilo (por ej., alquilo C1-6), -CN, -CF3, -O-alquilo(C1-6), -O-(haloalquilo(C1-6)), -C(O)-O-alquilo(C1-6), -alquilen-OH, haloalquilo(C1-6), hidroxialcoxi-, alcoxialcoxi-, y -S(O)2alquilo(C1-6); cada L1A se selecciona de modo independiente del grupo que consiste en: halogeno, alquilo, -CN, -CF3, -O-alquilo(C1-6), -O-(haloalquilo(C1-6)), -C(O)-O-alquilo(C1-6), -alquilen-OH, haloalquilo(C1-6), hidroxialcoxi-, alcoxialcoxi-, y -S(O)2alquilo(C1-6); y n es 0, 1, 2 o 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94803307P | 2007-07-05 | 2007-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067445A1 true AR067445A1 (es) | 2009-10-14 |
Family
ID=39830164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102867A AR067445A1 (es) | 2007-07-05 | 2008-07-02 | Inhibidores tetrahidropiranocromeno de gamma secretasa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8664411B2 (es) |
| EP (1) | EP2435416B1 (es) |
| JP (1) | JP5240871B2 (es) |
| KR (1) | KR20100044197A (es) |
| CN (1) | CN101754960A (es) |
| AR (1) | AR067445A1 (es) |
| AU (1) | AU2008275735B2 (es) |
| BR (1) | BRPI0814256A8 (es) |
| CA (1) | CA2691542A1 (es) |
| CL (1) | CL2008001960A1 (es) |
| CO (1) | CO6270309A2 (es) |
| EC (1) | ECSP109845A (es) |
| PE (1) | PE20090435A1 (es) |
| RU (1) | RU2483061C2 (es) |
| TW (1) | TW200908959A (es) |
| WO (1) | WO2009008980A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102702044A (zh) | 2006-01-20 | 2012-10-03 | 先灵公司 | 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物 |
| CL2008002084A1 (es) * | 2007-07-17 | 2009-01-23 | Schering Corp | Compuestos derivados de bencensulfonil cromano, tiocromano, tetrahidronaftaleno, inhibidores de la gamma secretasa; composicion farmaceutica que lo comprende; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas |
| CN102695546B (zh) | 2009-09-11 | 2014-09-10 | 前体生物药物股份公司 | 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物 |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| EP2693880A1 (en) * | 2011-04-04 | 2014-02-12 | Merck Sharp & Dohme Corp. | Gamma secretase inhibitors |
| EP2753623A4 (en) * | 2011-09-09 | 2015-01-28 | Merck Sharp & Dohme | GAMMASEKRETASEHEMMER |
| US9464103B2 (en) | 2012-11-29 | 2016-10-11 | Merck Sharp & Dohme Corp. | Spirocyclic sulfones as gamma secretase inhibitors |
| WO2014096212A1 (en) * | 2012-12-20 | 2014-06-26 | Janssen Pharmaceutica Nv | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS |
| KR102171710B1 (ko) | 2013-01-17 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체 |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| AR110152A1 (es) * | 2016-11-09 | 2019-02-27 | Bristol Myers Squibb Co | SULFONAS TRICÍCLICAS COMO MODULADORES DE RORg |
| US20230137562A1 (en) | 2017-06-07 | 2023-05-04 | Adrx, Inc. | Tau aggregation inhibitors |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| AU2018318319A1 (en) | 2017-08-18 | 2020-02-20 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20013000A3 (cs) | 1999-02-26 | 2002-02-13 | Merck & Co., Inc. | Nové sulfonamidové sloučeniny a jejich pouľití |
| FR2827590B1 (fr) * | 2001-07-18 | 2003-10-24 | Atuser | Transbordeur de liquides alimentaires usages |
| GB0108591D0 (en) * | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| PL372212A1 (en) * | 2001-08-03 | 2005-07-11 | Schering Corporation | Novel gamma secretase inhibitors |
| RU2202370C1 (ru) * | 2001-12-26 | 2003-04-20 | Эпштейн Олег Ильич | Нейропсихотропное лекарственное средство |
| GB0222833D0 (en) | 2002-10-02 | 2002-11-06 | Syngenta Ltd | Chemical process |
| GB0223039D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| ATE386028T1 (de) * | 2003-05-16 | 2008-03-15 | Merck Sharp & Dohme | Zyklohexylsulfone als gamma-sekretase-inhibitoren |
| GB0317491D0 (en) * | 2003-07-25 | 2003-08-27 | Novartis Ag | Organic compounds |
| DE102005062098A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Oxaphenanthren-Derivate |
| CN102702044A (zh) | 2006-01-20 | 2012-10-03 | 先灵公司 | 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物 |
| TW200813054A (en) | 2006-06-02 | 2008-03-16 | Elan Pharm Inc | Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| MX2011005046A (es) | 2008-11-13 | 2011-06-01 | Schering Corp | Moduladores de gamma secretasa. |
-
2008
- 2008-07-01 BR BRPI0814256A patent/BRPI0814256A8/pt not_active IP Right Cessation
- 2008-07-01 EP EP08768856.0A patent/EP2435416B1/en active Active
- 2008-07-01 CN CN200880023464A patent/CN101754960A/zh active Pending
- 2008-07-01 RU RU2010103716/04A patent/RU2483061C2/ru not_active IP Right Cessation
- 2008-07-01 WO PCT/US2008/008192 patent/WO2009008980A2/en not_active Ceased
- 2008-07-01 JP JP2010514862A patent/JP5240871B2/ja not_active Expired - Fee Related
- 2008-07-01 US US12/665,580 patent/US8664411B2/en active Active
- 2008-07-01 KR KR1020107002496A patent/KR20100044197A/ko not_active Withdrawn
- 2008-07-01 AU AU2008275735A patent/AU2008275735B2/en not_active Ceased
- 2008-07-01 CA CA002691542A patent/CA2691542A1/en not_active Abandoned
- 2008-07-02 TW TW097124900A patent/TW200908959A/zh unknown
- 2008-07-02 AR ARP080102867A patent/AR067445A1/es not_active Application Discontinuation
- 2008-07-02 PE PE2008001121A patent/PE20090435A1/es not_active Application Discontinuation
- 2008-07-02 CL CL2008001960A patent/CL2008001960A1/es unknown
-
2009
- 2009-12-30 CO CO09149364A patent/CO6270309A2/es not_active Application Discontinuation
-
2010
- 2010-01-05 EC EC2010009845A patent/ECSP109845A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2691542A1 (en) | 2009-01-15 |
| WO2009008980A2 (en) | 2009-01-15 |
| US20110236400A1 (en) | 2011-09-29 |
| ECSP109845A (es) | 2010-02-26 |
| BRPI0814256A8 (pt) | 2016-02-10 |
| WO2009008980A3 (en) | 2009-03-19 |
| US8664411B2 (en) | 2014-03-04 |
| RU2483061C2 (ru) | 2013-05-27 |
| PE20090435A1 (es) | 2009-04-18 |
| BRPI0814256A2 (pt) | 2015-02-03 |
| AU2008275735B2 (en) | 2014-03-27 |
| CO6270309A2 (es) | 2011-04-20 |
| CN101754960A (zh) | 2010-06-23 |
| AU2008275735A2 (en) | 2010-02-11 |
| AU2008275735A1 (en) | 2009-01-15 |
| JP2010532359A (ja) | 2010-10-07 |
| JP5240871B2 (ja) | 2013-07-17 |
| RU2010103716A (ru) | 2011-08-10 |
| CL2008001960A1 (es) | 2009-11-27 |
| EP2435416A2 (en) | 2012-04-04 |
| EP2435416B1 (en) | 2016-03-30 |
| TW200908959A (en) | 2009-03-01 |
| KR20100044197A (ko) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067445A1 (es) | Inhibidores tetrahidropiranocromeno de gamma secretasa | |
| AU2015265820B2 (en) | Cyclopropylamine compounds as histone demethylase inhibitors | |
| HRP20200680T1 (hr) | Postupak proizvodnje n-[3-(aminometil)oksetan-3-il]karbamatnih međuprodukata | |
| AR058554A1 (es) | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. | |
| PE20050377A1 (es) | Nuevos inhibidores de gamma secretasa | |
| PE20250674A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR041661A1 (es) | Compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos procesos para su preparacion y composiciones farmaceuticas que lo contienen | |
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| PE20040761A1 (es) | Compuestos de pirrolotriazona | |
| AR067896A1 (es) | Procedimiento para sintetizar compuestos utiles para tratar hepatitis c | |
| JP2016522172A5 (es) | ||
| PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| HRP20080541T3 (en) | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases | |
| DOP2007000014A (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR066781A1 (es) | Compuestos de imidazopirimidina inhibidores de cinasa | |
| AR045378A1 (es) | Analogos de quinazolina como inhibidores del receptor de tirosin quinasas | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales | |
| PE20080109A1 (es) | N-sulfonilacion selectiva de alcoholes sustituidos con 2-aminotrifluoralquilo | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |